BriaCell Therapeutics Corp Ordinary Shares BCTX 深 滬
等待開盤 11-26 09:30:00 美东时间
9.65
+1.150
+13.53%
華盛通- 最 高9.94
- 今 開8.63
- 成交量 6.04万股
- 最 低 8.60
- 昨 收 8.50
- 總市值 6538.94万
- 52周最高 190.50
- 市盈率 靜 --
- 換手率 0.89%
- 52周最低 6.00
- 委 比 -72.01%
- 總股本 677.61万
- 歷史最高 1860.5799
- 量 比 1.31
- 振 幅 15.76%
- 歷史最低 8.60
- 每 手 1
- 風險率 33.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal
11-25 20:37
BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that
11-18 20:32
BriaCell To Present Preclinical Data On Next-Gen Cancer Vaccine Platform At SITC 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
11-04 20:36
BriaCell Partners with MSK to Advance Cancer Immunotherapy
BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeu...
10-21 20:11
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
BriaCell Therapeutics Corp. collaborates with Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator Program to accelerate clinical development of Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy targeting metastatic breast cancer, prostate cancer, and other cancers. The partnership includes manufacturing, IND development, and clinical support for Bria-BRES+, BriaCell’s breast cancer therapy. MSK’s expertise will h...
10-21 11:30
BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues
10-20 19:33
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
BriaCell Therapeutics reports encouraging Phase 3 clinical data for Bria-IMT in metastatic breast cancer, showing similar biomarker trends as in the Phase 2 study and no new safety concerns. PFS data highlights Neutrophil to Lymphocyte Ratio (NLR) as a potential biomarker, with better outcomes for patients with NLR 0.7–2.3. The Phase 3 study remains blinded, with interim OS analysis planned upon 144 patient events.
10-20 11:30
BriaCell to Present Phase 3 Biomarker Data for Bria-IMT in Metastatic Breast Cancer at ESMO 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be presenting
10-13 19:34
BriaCell Therapeutics To Present Preclinical Bria-OTS+ Data At SITC Annual Meeting
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
10-03 19:37
HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Raises Price Target to $40
HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and raises the price target from $32 to $40.
08-27 18:12
